{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:34:31Z","timestamp":1790354071817,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jchf.2021.09.007","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T19:02:00Z","timestamp":1642014120000},"page":"119-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril\/Valsartan"],"prefix":"10.1016","volume":"10","author":[{"given":"Peder L.","family":"Myhre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret F.","family":"Prescott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary F.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2021.09.007_bib1","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.09.007_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A\u00a0test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.09.007_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jmb.2009.08.025","article-title":"Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation","volume":"393","author":"Pankow","year":"2009","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jchf.2021.09.007_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","article-title":"Effect of neprilysin inhibition on various natriuretic peptide assays","volume":"73","author":"Ibrahim","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.09.007_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1515\/BC.2004.036","article-title":"Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide","volume":"385","author":"Walther","year":"2004","journal-title":"Biol Chem"},{"key":"10.1016\/j.jchf.2021.09.007_bib6","first-page":"321","article-title":"Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?","volume":"6","author":"Mair","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.09.007_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ehf2.12251","article-title":"Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study","volume":"5","author":"Norberg","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.007_bib8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2021.09.007_bib9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-b-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2021.09.007_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0009-8981(01)00380-1","article-title":"Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system","volume":"305","author":"Shimizu","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jchf.2021.09.007_bib11","series-title":"Enhanced measurement of B-type natriuretic peptide through the use of BD P100 blood collection tubes containing protease inhibitors","author":"Apte","year":"2013"},{"key":"10.1016\/j.jchf.2021.09.007_bib12","first-page":"127","article-title":"Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction","volume":"9","author":"Murphy","year":"2021","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.09.007_bib13","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.1342","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","volume":"21","author":"Nougue","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.007_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ejhf.1589","article-title":"Sacubitril\/valsartan and B-type natriuretic peptide value: recalculating route","volume":"22","author":"Abellas-Sequeiros","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.007_bib15","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamacardio.2018.2568","article-title":"Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial","volume":"3","author":"Myhre","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2021.09.007_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006541","article-title":"Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction","volume":"13","author":"R\u00f8rth","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2021.09.007_bib17","first-page":"629","article-title":"Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure","volume":"3","author":"Vodovar","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.09.007_bib18","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.2337\/diabetes.52.9.2389","article-title":"B-Type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart. Importance of cyclic GMP","volume":"52","author":"Rosenkranz","year":"2003","journal-title":"Diabetes"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921004455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921004455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:59:51Z","timestamp":1761973191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177921004455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2213177921004455"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.09.007","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril\/Valsartan","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}